Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 56 entries
Sorted by: Best Match Show Resources per page
Impact of Polyethylene Glycol Functionalization of Graphene Oxide on Anticoagulation and Haemolytic Properties of Human Blood.

Materials (Basel, Switzerland)

Kamenska T, Abrashev M, Georgieva M, Krasteva N.
PMID: 34500942
Materials (Basel). 2021 Aug 26;14(17). doi: 10.3390/ma14174853.

Graphene oxide (GO) is one of the most explored nanomaterials in recent years. It has numerous biomedical applications as a nanomaterial including drug and gene delivery, contrast imaging, cancer treatment, etc. Since most of these applications need intravenous administration...

Cite
Kamenska T, Abrashev M, Georgieva M, et al. Impact of Polyethylene Glycol Functionalization of Graphene Oxide on Anticoagulation and Haemolytic Properties of Human Blood. Materials (Basel). 2021;14(17)doi: 10.3390/ma14174853.
Kamenska, T., Abrashev, M., Georgieva, M., & Krasteva, N. (2021). Impact of Polyethylene Glycol Functionalization of Graphene Oxide on Anticoagulation and Haemolytic Properties of Human Blood. Materials (Basel, Switzerland), 14(17), . https://doi.org/10.3390/ma14174853
Kamenska, Trayana, et al. "Impact of Polyethylene Glycol Functionalization of Graphene Oxide on Anticoagulation and Haemolytic Properties of Human Blood." Materials (Basel, Switzerland) vol. 14,17 (2021). doi: https://doi.org/10.3390/ma14174853
Kamenska T, Abrashev M, Georgieva M, Krasteva N. Impact of Polyethylene Glycol Functionalization of Graphene Oxide on Anticoagulation and Haemolytic Properties of Human Blood. Materials (Basel). 2021 Aug 26;14(17). doi: 10.3390/ma14174853. PMID: 34500942; PMCID: PMC8432731.
Copy Download .nbib Format: NLM
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.

Journal of thrombosis and thrombolysis

Whitaker C, McKinney A, Bollig R, Hieb N, Roberts RF, Rowe AS.
PMID: 34787787
J Thromb Thrombolysis. 2021 Nov 17; doi: 10.1007/s11239-021-02605-1. Epub 2021 Nov 17.

Factor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a...

Cite
Whitaker C, McKinney A, Bollig R, et al. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients. J Thromb Thrombolysis. 2021;doi: 10.1007/s11239-021-02605-1.
Whitaker, C., McKinney, A., Bollig, R., Hieb, N., Roberts, R. F., & Rowe, A. S. (2021). Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients. Journal of thrombosis and thrombolysis, . https://doi.org/10.1007/s11239-021-02605-1
Whitaker, Caitlyn, et al. "Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients." Journal of thrombosis and thrombolysis vol. (2021). doi: https://doi.org/10.1007/s11239-021-02605-1
Whitaker C, McKinney A, Bollig R, Hieb N, Roberts RF, Rowe AS. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients. J Thromb Thrombolysis. 2021 Nov 17; doi: 10.1007/s11239-021-02605-1. Epub 2021 Nov 17. PMID: 34787787.
Copy Download .nbib Format: NLM
Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle.

International journal of laboratory hematology

Gaudard M, Boissier E, Talon L, Douxfils J, Sapin AF, Sinegre T, Lebreton A.
PMID: 35029031
Int J Lab Hematol. 2022 Jan 13; doi: 10.1111/ijlh.13794. Epub 2022 Jan 13.

INTRODUCTION: Sample freezing is a part of routine laboratory tasks because some coagulation parameters are analysed in batches to optimize reagent consumption. The coagulation parameter stability in fresh and frozen samples has been described, but data are scarcer after...

Cite
Gaudard M, Boissier E, Talon L, et al. Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle. Int J Lab Hematol. 2022;doi: 10.1111/ijlh.13794.
Gaudard, M., Boissier, E., Talon, L., Douxfils, J., Sapin, A. F., Sinegre, T., & Lebreton, A. (2022). Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle. International journal of laboratory hematology, . https://doi.org/10.1111/ijlh.13794
Gaudard, Marion, et al. "Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle." International journal of laboratory hematology vol. (2022). doi: https://doi.org/10.1111/ijlh.13794
Gaudard M, Boissier E, Talon L, Douxfils J, Sapin AF, Sinegre T, Lebreton A. Stability of coagulation parameters in plasma samples at room temperature after one freeze/thaw cycle. Int J Lab Hematol. 2022 Jan 13; doi: 10.1111/ijlh.13794. Epub 2022 Jan 13. PMID: 35029031.
Copy Download .nbib Format: NLM
Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis.

Cell and tissue research

Maoz BM, Asplund M, Maggio N, Vlachos A.
PMID: 34850274
Cell Tissue Res. 2021 Dec 01; doi: 10.1007/s00441-021-03560-2. Epub 2021 Dec 01.

Blood coagulation factors can enter the brain under pathological conditions that affect the blood-brain interface. Besides their contribution to pathological brain states, such as neural hyperexcitability, neurodegeneration, and scar formation, coagulation factors have been linked to several physiological brain...

Cite
Maoz BM, Asplund M, Maggio N, et al. Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis. Cell Tissue Res. 2021;doi: 10.1007/s00441-021-03560-2.
Maoz, B. M., Asplund, M., Maggio, N., & Vlachos, A. (2021). Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis. Cell and tissue research, . https://doi.org/10.1007/s00441-021-03560-2
Maoz, Ben M, et al. "Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis." Cell and tissue research vol. (2021). doi: https://doi.org/10.1007/s00441-021-03560-2
Maoz BM, Asplund M, Maggio N, Vlachos A. Technology-based approaches toward a better understanding of neuro-coagulation in brain homeostasis. Cell Tissue Res. 2021 Dec 01; doi: 10.1007/s00441-021-03560-2. Epub 2021 Dec 01. PMID: 34850274.
Copy Download .nbib Format: NLM
Age of thawed plasma does not affect clinical outcomes or biomarker expression in patients receiving prehospital thawed plasma: a PAMPer secondary analysis.

Trauma surgery & acute care open

Reitz KM, Gruen DS, Guyette F, Brown JB, Yazer MH, Vodovotz Y, Johanssen PI, Stensballe J, Daley B, Miller RS, Harbrecht BG, Claridge J, Phelan HA, Neal MD, Zuckerbraun BS, Sperry JL.
PMID: 33634214
Trauma Surg Acute Care Open. 2021 Feb 11;6(1):e000648. doi: 10.1136/tsaco-2020-000648. eCollection 2021.

BACKGROUND: Prehospital plasma administration during air medical transport reduces the endotheliopathy of trauma, circulating pro-inflammatory cytokines, and 30-day mortality among traumatically injured patients at risk of hemorrhagic shock. No clinical data currently exists evaluating the age of thawed plasma...

Cite
Reitz KM, Gruen DS, Guyette F, et al. Age of thawed plasma does not affect clinical outcomes or biomarker expression in patients receiving prehospital thawed plasma: a PAMPer secondary analysis. Trauma Surg Acute Care Open. 2021;6(1):e000648doi: 10.1136/tsaco-2020-000648.
Reitz, K. M., Gruen, D. S., Guyette, F., Brown, J. B., Yazer, M. H., Vodovotz, Y., Johanssen, P. I., Stensballe, J., Daley, B., Miller, R. S., Harbrecht, B. G., Claridge, J., Phelan, H. A., Neal, M. D., Zuckerbraun, B. S., & Sperry, J. L. (2021). Age of thawed plasma does not affect clinical outcomes or biomarker expression in patients receiving prehospital thawed plasma: a PAMPer secondary analysis. Trauma surgery & acute care open, 6(1), e000648. https://doi.org/10.1136/tsaco-2020-000648
Reitz, Katherine M, et al. "Age of thawed plasma does not affect clinical outcomes or biomarker expression in patients receiving prehospital thawed plasma: a PAMPer secondary analysis." Trauma surgery & acute care open vol. 6,1 (2021): e000648. doi: https://doi.org/10.1136/tsaco-2020-000648
Reitz KM, Gruen DS, Guyette F, Brown JB, Yazer MH, Vodovotz Y, Johanssen PI, Stensballe J, Daley B, Miller RS, Harbrecht BG, Claridge J, Phelan HA, Neal MD, Zuckerbraun BS, Sperry JL. Age of thawed plasma does not affect clinical outcomes or biomarker expression in patients receiving prehospital thawed plasma: a PAMPer secondary analysis. Trauma Surg Acute Care Open. 2021 Feb 11;6(1):e000648. doi: 10.1136/tsaco-2020-000648. eCollection 2021. PMID: 33634214; PMCID: PMC7880105.
Copy Download .nbib Format: NLM
Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant.

Frontiers in cardiovascular medicine

Hamada M, Bhakta V, Andres SN, Sheffield WP.
PMID: 33816577
Front Cardiovasc Med. 2021 Mar 19;8:647405. doi: 10.3389/fcvm.2021.647405. eCollection 2021.

Alpha-1 antitrypsin (AAT, also known as alpha-1 proteinase inhibitor or SERPINA1) is the most abundant member of the serpin superfamily found in human plasma. The naturally occurring variant AAT M358R, altered at the P1 position of the critical reactive...

Cite
Hamada M, Bhakta V, Andres SN, et al. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant. Front Cardiovasc Med. 2021;8:647405doi: 10.3389/fcvm.2021.647405.
Hamada, M., Bhakta, V., Andres, S. N., & Sheffield, W. P. (2021). Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant. Frontiers in cardiovascular medicine, 8647405. https://doi.org/10.3389/fcvm.2021.647405
Hamada, Mostafa, et al. "Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant." Frontiers in cardiovascular medicine vol. 8 (2021): 647405. doi: https://doi.org/10.3389/fcvm.2021.647405
Hamada M, Bhakta V, Andres SN, Sheffield WP. Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant. Front Cardiovasc Med. 2021 Mar 19;8:647405. doi: 10.3389/fcvm.2021.647405. eCollection 2021. PMID: 33816577; PMCID: PMC8017132.
Copy Download .nbib Format: NLM
Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats.

Particle and fibre toxicology

Upadhyay S, Stoeger T, Harder V, Thomas RF, Schladweiler MC, Semmler-Behnke M, Takenaka S, Karg E, Reitmeir P, Bader M, Stampfl A, Kodavanti UP, Schulz H.
PMID: 19055790
Part Fibre Toxicol. 2008 Dec 04;5:19. doi: 10.1186/1743-8977-5-19.

BACKGROUND: Exposure to particulate matter is a risk factor for cardiopulmonary disease but the underlying molecular mechanisms remain poorly understood. In the present study we sought to investigate the cardiopulmonary responses on spontaneously hypertensive rats (SHRs) following inhalation of...

Cite
Upadhyay S, Stoeger T, Harder V, et al. Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats. Part Fibre Toxicol. 2008;5:19doi: 10.1186/1743-8977-5-19.
Upadhyay, S., Stoeger, T., Harder, V., Thomas, R. F., Schladweiler, M. C., Semmler-Behnke, M., Takenaka, S., Karg, E., Reitmeir, P., Bader, M., Stampfl, A., Kodavanti, U. P., & Schulz, H. (2008). Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats. Particle and fibre toxicology, 519. https://doi.org/10.1186/1743-8977-5-19
Upadhyay, Swapna, et al. "Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats." Particle and fibre toxicology vol. 5 (2008): 19. doi: https://doi.org/10.1186/1743-8977-5-19
Upadhyay S, Stoeger T, Harder V, Thomas RF, Schladweiler MC, Semmler-Behnke M, Takenaka S, Karg E, Reitmeir P, Bader M, Stampfl A, Kodavanti UP, Schulz H. Exposure to ultrafine carbon particles at levels below detectable pulmonary inflammation affects cardiovascular performance in spontaneously hypertensive rats. Part Fibre Toxicol. 2008 Dec 04;5:19. doi: 10.1186/1743-8977-5-19. PMID: 19055790; PMCID: PMC2612692.
Copy Download .nbib Format: NLM
Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Zeitler H, Ulrich-Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J.
PMID: 22969696
Transfus Med Hemother. 2012 Aug;39(4):264-270. doi: 10.1159/000341913. Epub 2012 Jul 26.

OBJECTIVES: In acquired hemophilia (AH), autoantibodies (inhibitors) impede blood coagulation factors leading to severe bleedings. Cornerstones of a successful treatment are the control of bleeding and an eradication of autoantibodies. The present study is an update of our previous...

Cite
Zeitler H, Ulrich-Merzenich G, Panek D, et al. Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia. Transfus Med Hemother. 2012;39(4):264-270doi: 10.1159/000341913.
Zeitler, H., Ulrich-Merzenich, G., Panek, D., Goldmann, G., Vidovic, N., Brackmann, H. H., & Oldenburg, J. (2012). Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 39(4), 264-270. https://doi.org/10.1159/000341913
Zeitler, Heike, et al. "Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 39,4 (2012): 264-270. doi: https://doi.org/10.1159/000341913
Zeitler H, Ulrich-Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J. Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia. Transfus Med Hemother. 2012 Aug;39(4):264-270. doi: 10.1159/000341913. Epub 2012 Jul 26. PMID: 22969696; PMCID: PMC3434332.
Copy Download .nbib Format: NLM
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A.

Neuropsychiatric disease and treatment

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S.
PMID: 24876778
Neuropsychiatr Dis Treat. 2014 May 16;10:865-7. doi: 10.2147/NDT.S61816. eCollection 2014.

Electroconvulsive therapy (ECT) is used for medication-resistant and life-threatening mental disorders, and therefore it occupies an important position in psychiatric treatment. ECT reportedly increases intracranial pressure and is suspected of increasing the risk of intracranial hemorrhage, especially in patients...

Cite
Saito N, Shioda K, Nisijima K, et al. Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A. Neuropsychiatr Dis Treat. 2014;10:865-7doi: 10.2147/NDT.S61816.
Saito, N., Shioda, K., Nisijima, K., Kobayashi, T., & Kato, S. (2014). Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A. Neuropsychiatric disease and treatment, 10865-7. https://doi.org/10.2147/NDT.S61816
Saito, Nobuyoshi, et al. "Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A." Neuropsychiatric disease and treatment vol. 10 (2014): 865-7. doi: https://doi.org/10.2147/NDT.S61816
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S. Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A. Neuropsychiatr Dis Treat. 2014 May 16;10:865-7. doi: 10.2147/NDT.S61816. eCollection 2014. PMID: 24876778; PMCID: PMC4037299.
Copy Download .nbib Format: NLM
Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report.

Oncology letters

Lin XY, Yang ZG, Zhang P, Liu YP, Wang CX, Shao GG.
PMID: 26722282
Oncol Lett. 2015 Nov;10(5):3018-3020. doi: 10.3892/ol.2015.3717. Epub 2015 Sep 17.

Hemophilia is a hereditary disease with impaired blood coagulation due to a genetic deficiency of blood coagulation factors. Hemophilia often causes spontaneous life-threatening bleeding, so patients with hemophilia are often not suitable for any surgery that may cause iatrogenic...

Cite
Lin XY, Yang ZG, Zhang P, et al. Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report. Oncol Lett. 2015;10(5):3018-3020doi: 10.3892/ol.2015.3717.
Lin, X. Y., Yang, Z. G., Zhang, P., Liu, Y. P., Wang, C. X., & Shao, G. G. (2015). Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report. Oncology letters, 10(5), 3018-3020. https://doi.org/10.3892/ol.2015.3717
Lin, Xing-Yu, et al. "Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report." Oncology letters vol. 10,5 (2015): 3018-3020. doi: https://doi.org/10.3892/ol.2015.3717
Lin XY, Yang ZG, Zhang P, Liu YP, Wang CX, Shao GG. Thoracoscopic lobectomy in a lung cancer patient with severe hemophilia: A case report. Oncol Lett. 2015 Nov;10(5):3018-3020. doi: 10.3892/ol.2015.3717. Epub 2015 Sep 17. PMID: 26722282; PMCID: PMC4665935.
Copy Download .nbib Format: NLM
In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus.

Research and practice in thrombosis and haemostasis

Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV.
PMID: 30349890
Res Pract Thromb Haemost. 2018 Sep 11;2(4):708-717. doi: 10.1002/rth2.12147. eCollection 2018 Oct.

BACKGROUND: Effective HIV treatment with antiretroviral therapy has prolonged survival and shifted causes of death to non-AIDS illnesses such as cardiovascular disease. We have shown that inflammation and HIV viral load associate with pro- and anticoagulant factor imbalances resulting...

Cite
Brummel-Ziedins KE, Gissel M, Neuhaus J, et al. In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. Res Pract Thromb Haemost. 2018;2(4):708-717doi: 10.1002/rth2.12147.
Brummel-Ziedins, K. E., Gissel, M., Neuhaus, J., Borges, �. �. H., Chadwick, D. R., Emery, S., Neaton, J. D., Tracy, R. P., Baker, J. V. (2018). In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. Research and practice in thrombosis and haemostasis, 2(4), 708-717. https://doi.org/10.1002/rth2.12147
Brummel-Ziedins, Kathleen E, et al. "In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus." Research and practice in thrombosis and haemostasis vol. 2,4 (2018): 708-717. doi: https://doi.org/10.1002/rth2.12147
Brummel-Ziedins KE, Gissel M, Neuhaus J, Borges ÁH, Chadwick DR, Emery S, Neaton JD, Tracy RP, Baker JV. In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus. Res Pract Thromb Haemost. 2018 Sep 11;2(4):708-717. doi: 10.1002/rth2.12147. eCollection 2018 Oct. PMID: 30349890; PMCID: PMC6178732.
Copy Download .nbib Format: NLM
Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems.

Frontiers in plant science

Top O, Geisen U, Decker EL, Reski R.
PMID: 30899272
Front Plant Sci. 2019 Mar 07;10:261. doi: 10.3389/fpls.2019.00261. eCollection 2019.

The use of plants as production platforms for pharmaceutical proteins has been on the rise for the past two decades. The first marketed plant-made pharmaceutical, taliglucerase alfa against Gaucher's disease produced in carrot cells by Pfizer/Protalix Biotherapeutics, was approved...

Cite
Top O, Geisen U, Decker EL, et al. Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems. Front Plant Sci. 2019;10:261doi: 10.3389/fpls.2019.00261.
Top, O., Geisen, U., Decker, E. L., & Reski, R. (2019). Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems. Frontiers in plant science, 10261. https://doi.org/10.3389/fpls.2019.00261
Top, Oguz, et al. "Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems." Frontiers in plant science vol. 10 (2019): 261. doi: https://doi.org/10.3389/fpls.2019.00261
Top O, Geisen U, Decker EL, Reski R. Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems. Front Plant Sci. 2019 Mar 07;10:261. doi: 10.3389/fpls.2019.00261. eCollection 2019. PMID: 30899272; PMCID: PMC6417376.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 56 entries